• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket

    7/11/23 8:33:53 AM ET
    $ABOS
    $BTTX
    $CACO
    $CNEY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABOS alert in real time by email

    Gainers

    • CytoMed Therapeutics Limited (NASDAQ:GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) shares gained 51.1% to $1.36 in pre-market trading after the FDA approved the company's AspyreRx prescription-only digital therapeutic treatment to provide cognitive behavioral therapy to adult patients with type 2 diabetes.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 42.2% to $0.1450 in pre-market trading after declining around 14% on Monday.
    • Trinity Place Holdings Inc. (NYSE:TPHS) gained 24.1% to $0.6790 in pre-market trading after declining around 15% on Monday.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares rose 20.8% to $0.54 in pre-market trading.
    • NanoViricides, Inc. (NYSE:NNVC) rose 19.9% to $1.69 in pre-market trading. NanoViricides reported effectiveness of antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with respiratory syncytial virus.
    • Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares climbed 18.2% to $5.86 in pre-market trading. Acumen Pharmaceuticals recently announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
    • CN Energy Group. Inc. (NASDAQ:CNEY) rose 15.6% to $0.2110 in pre-market trading after falling around 6% on Monday.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) gained 14.5% to $0.1811 in pre-market trading after jumping around 37% on Monday.
    • Caravelle International Group (NASDAQ:CACO) shares gained 12.6% to $0.6190 in pre-market trading.

    Losers

    • DSS, Inc. (NYSE:DSS) fell 17.1% to $0.3002 in pre-market trading. DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc, named Daniel Lew as Chief Investment Officer and Portfolio Manager.
    • Viridian Therapeutics, Inc. (NASDAQ:VRDN) fell 14.4% to $20.99 in pre-market trading after announcing data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients with chronic thyroid eye disease.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell 12.5% to $7.69 in pre-market trading as the company priced its underwritten public offering of 20,000,000 shares at $7.50 per share.
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) fell 11.9% to $0.4845 in pre-market trading. Jupiter Wellness shares jumped over 50% on Monday after the company announced it has executed an Asset Purchase Agreement with GBB Drink Lab to acquire all operating assets including the "Safety Shot" rapid alcohol detox drink.
    • REE Automotive Ltd. (NASDAQ:REE) shares dropped 10.5% to $0.34 in pre-market trading. REE Automotive recently named Carlton Rose, former global president of fleet maintenance and engineering at UPS, to the company’s board of directors.
    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 10.1% to $0.1889 in pre-market trading after declining 19% on Monday. Tattooed Chef recently announced it intends to file for voluntary Chapter 11 Bankruptcy protection.
    • Journey Medical Corporation (NASDAQ:DERM) shares fell 9.2% to $2.58 in pre-market trading after climbing around 21% on Monday.
    • EZFill Holdings Inc. (NASDAQ:EZFL) fell 9.1% to $2.00 in pre-market. EzFill achieved another quarterly record for gallons delivered in the second quarter.
    • urban-gro, Inc. (NASDAQ:UGRO) shares fell 8.1% to $1.83 in pre-market trading after rising around 5% on Monday.
    • Ryvyl Inc. (NASDAQ:RVYL) fell 7.8% to $1.07 in pre-market trading after gaining over 5% on Monday.

     

    Now Read This: Market Volatility Increases Ahead Of Inflation Reports; S&P 500 Settles Higher

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $BTTX
    $CACO
    $CNEY

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Viridian Therapeutics Inc.
    $VRDN
    12/10/2025$42.00 → $47.00Outperform
    Wedbush
    Viridian Therapeutics Inc.
    $VRDN
    12/3/2025Outperform
    William Blair
    Viridian Therapeutics Inc.
    $VRDN
    11/24/2025Buy
    Truist
    Viridian Therapeutics Inc.
    $VRDN
    8/25/2025$44.00Buy
    Jefferies
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    More analyst ratings

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Alloush Ramsey was granted 46,863 shares, increasing direct ownership by 8% to 598,543 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    4/24/26 5:29:55 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Benesch Joseph was granted 28,907 shares, increasing direct ownership by 12% to 261,371 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    4/24/26 5:28:53 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Maraoui Claude was granted 49,277 shares, increasing direct ownership by 2% to 2,435,990 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    4/24/26 5:27:06 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Large owner S8 Global Fintech & Regtech Fund bought $71,180 worth of shares (200,000 units at $0.36), increasing direct ownership by 6% to 3,604,845 units (SEC Form 4)

    4 - RYVYL Inc. (0001419275) (Issuer)

    7/17/25 9:00:26 AM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    Large owner S8 Global Fintech & Regtech Fund bought $91,050 worth of shares (114,491 units at $0.80), increasing direct ownership by 3% to 3,504,845 units (SEC Form 4)

    4 - RYVYL Inc. (0001419275) (Issuer)

    7/1/25 9:00:07 AM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    $ABOS
    $BTTX
    $CACO
    $CNEY
    SEC Filings

    View All

    urban-gro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - urban-gro, Inc. (0001706524) (Filer)

    4/24/26 4:57:52 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Amendment: SEC Form S-1/A filed by DSS Inc.

    S-1/A - DSS, INC. (0000771999) (Filer)

    4/24/26 4:05:48 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.

    DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

    4/23/26 4:31:13 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Viridian Therapeutics with a new price target

    Wedbush reiterated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $47.00 from $42.00 previously

    12/10/25 9:29:14 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms July 10 – August 5, 2026 and Four Venues for Lanka Premier League Season 6; Tournament Conducted in Partnership with UGRO Subsidiary IPG Group

    LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket ("SLC") confirming the dates, venues, and player-registration timeline for Lanka Premier League ("LPL") Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC ("IPG"), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements. Season 6 — By the Numbers Tournament windowJuly 10 – August 5, 2026 (

    4/23/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

    SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions o

    4/21/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on April 16, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 135,470 shares of Iovance's common stock to twelve new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 1

    4/17/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Leadership Updates

    Live Leadership Updates

    View All

    urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms July 10 – August 5, 2026 and Four Venues for Lanka Premier League Season 6; Tournament Conducted in Partnership with UGRO Subsidiary IPG Group

    LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket ("SLC") confirming the dates, venues, and player-registration timeline for Lanka Premier League ("LPL") Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC ("IPG"), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements. Season 6 — By the Numbers Tournament windowJuly 10 – August 5, 2026 (

    4/23/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 — Potential Record 600-Player Pool, World-Class Marquee Talent, and Expected Appointment of Chris Gayle as Global Brand Ambassador

    LAFAYETTE, Colo., April 13, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., a vertically integrated sports, media, and experiential platform, today announced that Lanka Premier League ("LPL") Season 6 — executed via its subsidiary Innovative Production Group FZ, LLC ("IPG") platform — is expecting record-breaking expansion. Season 6 is projected to feature the largest-ever LPL player registration pool of 500 to 600 athletes expected to be drawn from the world's top cricketing nations, elevated by a marquee roster of global superstars and the expected appointment of T20 legend Chris Gayle as official Brand

    4/13/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Roundtable CEO James Heckman Clarifies Equity Status, Announces One Year Lock

    Ryvyl Adds Veteran former Goldman Sachs Tech Banker Steve Fletcher to Board of Directors In photo: James Heckman, Roundtable Founder and CEO  Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) -- James Heckman, CEO of AI-driven, Web3 media platform - RTB Digital, Inc. (dba "Roundtable"), following shareholder approval of the company's merger with RYVYL Inc. (NASDAQ:RVYL) outlined the post-merger capitalization table lock-up agreement, and related liquidity considerations; provided additional detail on the recently announced $10 million deposit toward a strategic investment and partnership; and announced a veteran digital media-focused board member. Heckman announced, "about 85% of outstandi

    4/2/26 3:45:00 PM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Financials

    Live finance-specific insights

    View All

    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

    - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist

    3/30/26 7:01:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

    Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceut

    3/26/26 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

    3/25/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by DSS Inc.

    SC 13D/A - DSS, INC. (0000771999) (Subject)

    12/12/24 9:56:52 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care